Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today

DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.

Zacks Investment Research • Jan 8, 2026

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.

Zacks Investment Research • Dec 23, 2025

4 Outpatient Home Health Stocks in Focus as Market Dynamics Change

An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.

Zacks Investment Research • Dec 19, 2025

Here's Why You Should Hold DaVita Stock in Your Portfolio for Now

DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

Zacks Investment Research • Dec 18, 2025

DaVita Names New Leaders to Accelerate Care Transformation

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) and Steve Phillips will serve as Chief Strategy Officer (CSO), effective immediately. Both leaders bring more than a decade of proven success at DaVita and deep expertise that will help shape the company's next chapter of growth and innovation.

PRNewsWire • Dec 11, 2025

DaVita: More Volatile But Better Upside Than Fresenius

DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.

Seeking Alpha • Dec 3, 2025

Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 28, 2025

DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.

Seeking Alpha • Nov 17, 2025

DaVita Inc. to Participate in Fireside Chat with Wolfe Research

DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025, at 11:20 am EST. To view the live webcast, visit the Wolfe Research page here and create a free registration.

PRNewsWire • Nov 14, 2025

DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025

Six  new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more.

PRNewsWire • Nov 4, 2025